Siragen Pharmaceuticals, Inc. was named one of the fastest growing, most exciting start ups in San Diego in 2016, by the San Diego Venture Group (SDVG). Siragen Pharmaceuticals will present at the San Diego Venture Summit, September 7th-8th at the Hilton Bayfront, San Diego, USA. Dr. Mohamedi Kagalwala (Co-Founder & CSO) will be presenting scientific updates on September 7th. This update will be followed by a booth presentation of Siragen Pharmaceuticals on September 8th at the Hilton Bayfront. Siragen invites everyone to attend the Venture Summit and requests the pleasure to meet all attendees at our booth on September 8th.
Siragen Pharmaceuticals will be represented by its Founder-CEO, Michel Levesque, MD, in San Francisco, CA, on June 6-9, 2016. Dr Levesque will meet interested partners and potential collaborators at several one-on-one meetings. A lot of interest has been raised by this new spinoff from Neurogeneration and its proprietary small lead molecules discoveries addressing the large unmet needs of patients with neurodegenerative disorders and Alzheimer’s disease.
Following rapid development with its drug discovery program, Neurogeneration announces it was spinning off Siragen Pharmaceuticals, Inc., dedicated to expand its small molecules discoveries to treat neurodegenerative disorders like Alzheimers’disease. Siragen’s co-founders, Drs Kagalwala and Levesque, will continue in their roles as CSO and CEO respectively. The creation of Siragen Pharmaceuticals coincides with the recent filing of patents for its proprietary molecules, and follows a seed investment from private investors. Neurogeneration remains committed to its clinical cell therapy program for Parkinson’s disease and other degenerative disorders of the Central Nervous System.